Trial Profile
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs MM-151 (Primary) ; Irinotecan
- Indications Breast cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Merrimack Pharmaceuticals
- 07 Jun 2016 Final results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2016 Results published in a Merrimack Pharmaceuticals media release.
- 18 May 2016 Results will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Merrimack Pharmaceuticals media release.